Telemus Capital LLC Buys Shares of 2,000 Ascendis Pharma A/S (ASND)

Telemus Capital LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the first quarter, HoldingsChannel reports. The firm bought 2,000 shares of the biotechnology company’s stock, valued at approximately $235,000.

Several other hedge funds have also modified their holdings of ASND. BlackRock Inc. raised its position in Ascendis Pharma A/S by 5.1% in the 3rd quarter. BlackRock Inc. now owns 460,961 shares of the biotechnology company’s stock worth $32,663,000 after buying an additional 22,172 shares during the last quarter. Morgan Stanley raised its position in Ascendis Pharma A/S by 53.6% in the 3rd quarter. Morgan Stanley now owns 47,100 shares of the biotechnology company’s stock worth $3,338,000 after buying an additional 16,434 shares during the last quarter. Quantamental Technologies LLC purchased a new position in Ascendis Pharma A/S in the 4th quarter worth about $25,000. SG Americas Securities LLC purchased a new position in Ascendis Pharma A/S in the 4th quarter worth about $116,000. Finally, TD Asset Management Inc. raised its position in Ascendis Pharma A/S by 15.8% in the 4th quarter. TD Asset Management Inc. now owns 76,672 shares of the biotechnology company’s stock worth $4,804,000 after buying an additional 10,436 shares during the last quarter. 94.86% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts have recently commented on ASND shares. Wedbush reaffirmed a “buy” rating and set a $217.00 price target on shares of Ascendis Pharma A/S in a research report on Tuesday, March 26th. Zacks Investment Research raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating and set a $82.00 price target for the company in a research report on Friday, January 18th. Cantor Fitzgerald started coverage on shares of Ascendis Pharma A/S in a research report on Wednesday, January 23rd. They set an “overweight” rating and a $102.00 price target for the company. JPMorgan Chase & Co. upped their price target on shares of Ascendis Pharma A/S from $85.00 to $145.00 and gave the company an “overweight” rating in a research report on Thursday, March 7th. Finally, BidaskClub lowered shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Friday, April 19th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $135.56.

NASDAQ ASND opened at $121.59 on Friday. Ascendis Pharma A/S has a 52 week low of $53.21 and a 52 week high of $131.76. The stock has a market cap of $5.09 billion, a PE ratio of -32.51 and a beta of 0.94.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Wednesday, April 3rd. The biotechnology company reported ($0.87) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.17) by $0.30. Ascendis Pharma A/S had a negative net margin of 1,275.08% and a negative return on equity of 40.86%. The firm had revenue of $12.00 million during the quarter. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -3.93 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Telemus Capital LLC Buys Shares of 2,000 Ascendis Pharma A/S (ASND)” was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/05/10/telemus-capital-llc-buys-shares-of-2000-ascendis-pharma-a-s-asnd.html.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Further Reading: Stop Order Uses For Individual Investors

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.